Current treatment for primary ciliary dyskinesia conditions

Young Yoo, Young Yull Koh

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)


Primary ciliary dyskinesia (PCD) is a heterogeneous group of conditions characterised by ultrastructural defects of the cilia, which result in impaired mucociliary clearance. Although the incidence of PCD is low, early recognition and prompt management are important in order to prevent unnecessary morbidity, the progression of bronchiectasis and the deterioration of lung function. As the underlying defect in PCD cannot be corrected, the mainstay of therapy remains effective clearance of airway secretions and antibiotic therapy of respiratory tract infections. This paper highlights new developments in the field that have implications for the future management of PCD. These include β-adrenergic agonists, arginine, uridine-5′-triphosphate, hypertonic saline and recombinant human DNase. It is to be hoped that these treatment modalities will have a therapeutic role in PCD.

Original languageEnglish
Pages (from-to)369-377
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Issue number2
Publication statusPublished - 2004 Feb
Externally publishedYes


  • Arginine
  • Current treatment
  • Hypertonic saline
  • Mucociliary clearance
  • Primary ciliary dyskinesia
  • Recombinant human DNase
  • Uridine-5′-triphosphate
  • β-adrenergic agonists

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Current treatment for primary ciliary dyskinesia conditions'. Together they form a unique fingerprint.

Cite this